Viracta Historical Balance Sheet

VIRX Stock

USD 0.16 0.02 14.29%

Trend analysis of Viracta Therapeutics balance sheet accounts such as Total Assets of 54.4 M, Short Long Term Debt Total of 14.3 M, Other Current Liabilities of 5.5 M or Total Current Liabilities of 40.3 M provides information on Viracta Therapeutics' total assets, liabilities, and equity, which is the actual value of Viracta Therapeutics to its prevalent stockholders. By breaking down trends over time using Viracta Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Viracta Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Viracta Therapeutics is a good buy for the upcoming year.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viracta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Viracta Stock please use our How to Invest in Viracta Therapeutics guide.

About Viracta Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Viracta Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Viracta Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Viracta Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Viracta currently owns. An asset can also be divided into two categories, current and non-current.

Viracta Therapeutics Balance Sheet Chart

At this time, Viracta Therapeutics' Property Plant And Equipment Gross is fairly stable compared to the past year. Accumulated Other Comprehensive Income is likely to rise to 9,450 in 2024, whereas Total Assets are likely to drop slightly above 54.4 M in 2024.

Short Long Term Debt Total Other Current Liab Retained Earnings Accounts Payable

Add Fundamental

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Accounts Payable

An accounting item on the balance sheet that represents Viracta Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Viracta Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Viracta Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Viracta Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viracta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Viracta Stock please use our How to Invest in Viracta Therapeutics guide.At this time, Viracta Therapeutics' Property Plant And Equipment Gross is fairly stable compared to the past year. Accumulated Other Comprehensive Income is likely to rise to 9,450 in 2024, whereas Total Assets are likely to drop slightly above 54.4 M in 2024.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	5.5M	25.2M	25.6M	14.3M
Total Assets	108.6M	96.0M	56.7M	54.4M

Short Long Term Debt Total Total Assets

Viracta Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt
Total Assets		0.15	0.19	-0.02	0.67	0.16	-0.06	-0.48	0.65	0.34	0.69	0.55	0.57	1.0	-0.15	0.6	0.25	0.15	0.74	-0.02	0.13	0.17	1.0	-0.2	-0.14	0.3
Short Long Term Debt Total	0.15		0.47	0.21	0.03	-0.38	0.51	0.64	0.09	-0.36	-0.35	-0.29	-0.14	0.17	-0.03	0.19	0.66	0.0	0.13	0.3	0.11	-0.34	0.18	0.23	-0.01	0.44
Other Current Liab	0.19	0.47		0.68	-0.14	-0.36	0.72	0.32	-0.02	-0.22	-0.21	-0.37	-0.14	0.22	0.11	-0.04	0.52	0.01	-0.04	0.23	0.39	-0.32	0.22	0.21	0.13	0.25
Total Current Liabilities	-0.02	0.21	0.68		-0.2	-0.23	0.25	0.41	0.0	-0.02	-0.3	-0.27	0.03	-0.01	0.18	0.34	0.34	-0.25	-0.23	0.19	0.21	-0.18	-0.01	0.82	0.2	0.63
Total Stockholder Equity	0.67	0.03	-0.14	-0.2		0.17	-0.16	-0.38	0.1	0.41	0.5	0.55	0.67	0.65	0.1	0.48	0.13	-0.54	0.77	-0.15	-0.64	0.29	0.66	-0.18	0.16	0.14
Property Plant And Equipment Net	0.16	-0.38	-0.36	-0.23	0.17		-0.07	-0.22	0.49	0.14	0.12	0.8	-0.14	0.11	-0.27	0.0	-0.06	0.07	0.19	-0.93	-0.06	0.98	0.12	-0.2	-0.27	0.0
Current Deferred Revenue	-0.06	0.51	0.72	0.25	-0.16	-0.07		0.43	-0.1	-0.53	-0.36	-0.32	-0.52	-0.04	0.09	-0.47	0.4	0.01	-0.11	-0.13	0.17	-0.03	-0.04	-0.11	0.1	-0.1
Net Debt	-0.48	0.64	0.32	0.41	-0.38	-0.22	0.43		-0.33	-0.49	-0.92	-0.5	-0.45	-0.47	0.09	-0.13	0.64	-0.19	-0.32	0.05	0.0	-0.17	-0.47	0.47	0.12	0.45
Retained Earnings	0.65	0.09	-0.02	0.0	0.1	0.49	-0.1	-0.33		0.28	0.51	0.62	0.19	0.63	-0.47	0.5	0.03	0.54	0.32	-0.29	0.51	0.39	0.63	-0.01	-0.51	0.36
Accounts Payable	0.34	-0.36	-0.22	-0.02	0.41	0.14	-0.53	-0.49	0.28		0.45	0.4	0.8	0.33	-0.08	0.43	-0.22	-0.2	0.23	-0.09	-0.21	0.15	0.32	0.03	-0.07	0.25
Cash	0.69	-0.35	-0.21	-0.3	0.5	0.12	-0.36	-0.92	0.51	0.45		0.5	0.56	0.69	-0.13	0.38	-0.51	0.2	0.47	0.1	0.05	0.08	0.68	-0.33	-0.15	-0.22
Non Current Assets Total	0.55	-0.29	-0.37	-0.27	0.55	0.8	-0.32	-0.5	0.62	0.4	0.5		0.32	0.5	-0.36	0.42	-0.09	-0.02	0.55	-0.68	-0.17	0.81	0.51	-0.19	-0.34	0.12
Non Currrent Assets Other	0.57	-0.14	-0.14	0.03	0.67	-0.14	-0.52	-0.45	0.19	0.8	0.56	0.32		0.57	-0.07	0.63	-0.09	-0.31	0.41	0.2	-0.32	-0.09	0.57	0.09	-0.04	0.33
Cash And Short Term Investments	1.0	0.17	0.22	-0.01	0.65	0.11	-0.04	-0.47	0.63	0.33	0.69	0.5	0.57		-0.13	0.59	0.25	0.17	0.71	0.02	0.16	0.12	1.0	-0.2	-0.12	0.29
Common Stock Total Equity	-0.15	-0.03	0.11	0.18	0.1	-0.27	0.09	0.09	-0.47	-0.08	-0.13	-0.36	-0.07	-0.13		-0.09	-0.02	-0.38	-0.06	0.3	-0.29	-0.21	-0.13	0.18	1.0	-0.04
Common Stock Shares Outstanding	0.6	0.19	-0.04	0.34	0.48	0.0	-0.47	-0.13	0.5	0.43	0.38	0.42	0.63	0.59	-0.09		0.2	-0.17	0.53	0.17	-0.06	0.03	0.6	0.5	-0.08	0.76
Short Term Investments	0.25	0.66	0.52	0.34	0.13	-0.06	0.4	0.64	0.03	-0.22	-0.51	-0.09	-0.09	0.25	-0.02	0.2		-0.09	0.28	-0.09	0.09	0.02	0.26	0.15	0.02	0.59
Non Current Liabilities Total	0.15	0.0	0.01	-0.25	-0.54	0.07	0.01	-0.19	0.54	-0.2	0.2	-0.02	-0.31	0.17	-0.38	-0.17	-0.09		-0.15	0.07	0.89	-0.1	0.15	-0.36	-0.46	-0.18
Other Current Assets	0.74	0.13	-0.04	-0.23	0.77	0.19	-0.11	-0.32	0.32	0.23	0.47	0.55	0.41	0.71	-0.06	0.53	0.28	-0.15		-0.12	-0.27	0.26	0.73	-0.31	-0.02	0.2
Other Stockholder Equity	-0.02	0.3	0.23	0.19	-0.15	-0.93	-0.13	0.05	-0.29	-0.09	0.1	-0.68	0.2	0.02	0.3	0.17	-0.09	0.07	-0.12		0.16	-0.95	0.01	0.24	0.28	0.03
Total Liab	0.13	0.11	0.39	0.21	-0.64	-0.06	0.17	0.0	0.51	-0.21	0.05	-0.17	-0.32	0.16	-0.29	-0.06	0.09	0.89	-0.27	0.16		-0.21	0.15	-0.02	-0.35	0.07
Property Plant And Equipment Gross	0.17	-0.34	-0.32	-0.18	0.29	0.98	-0.03	-0.17	0.39	0.15	0.08	0.81	-0.09	0.12	-0.21	0.03	0.02	-0.1	0.26	-0.95	-0.21		0.13	-0.16	-0.2	0.05
Total Current Assets	1.0	0.18	0.22	-0.01	0.66	0.12	-0.04	-0.47	0.63	0.32	0.68	0.51	0.57	1.0	-0.13	0.6	0.26	0.15	0.73	0.01	0.15	0.13		-0.2	-0.12	0.3
Short Term Debt	-0.2	0.23	0.21	0.82	-0.18	-0.2	-0.11	0.47	-0.01	0.03	-0.33	-0.19	0.09	-0.2	0.18	0.5	0.15	-0.36	-0.31	0.24	-0.02	-0.16	-0.2		0.19	0.69
Common Stock	-0.14	-0.01	0.13	0.2	0.16	-0.27	0.1	0.12	-0.51	-0.07	-0.15	-0.34	-0.04	-0.12	1.0	-0.08	0.02	-0.46	-0.02	0.28	-0.35	-0.2	-0.12	0.19		-0.02
Long Term Debt	0.3	0.44	0.25	0.63	0.14	0.0	-0.1	0.45	0.36	0.25	-0.22	0.12	0.33	0.29	-0.04	0.76	0.59	-0.18	0.2	0.03	0.07	0.05	0.3	0.69	-0.02

Click cells to compare fundamentals

Viracta Therapeutics Account Relationship Matchups

Viracta Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	37.2M	48.3M	108.6M	96.0M	56.7M	54.4M
Short Long Term Debt Total	6.3M	6.2M	5.5M	25.2M	25.6M	14.3M
Other Current Liab	2.5M	3.4M	5.4M	6.9M	10.1M	5.5M
Total Current Liabilities	9.4M	6.3M	9.1M	10.0M	38.4M	40.3M
Total Stockholder Equity	27.5M	(46.2M)	94.4M	61.1M	18.3M	19.5M
Property Plant And Equipment Net	820K	1.0M	882K	414K	464K	749.7K
Net Debt	(12.0M)	(40.9M)	(98.1M)	(11.6M)	13.2M	13.9M
Retained Earnings	(682.8M)	(50.9M)	(165.7M)	(214.9M)	(265.9M)	(279.2M)
Accounts Payable	791K	1.6M	2.9M	2.5M	2.4M	1.7M
Cash	18.3M	47.1M	103.6M	36.8M	12.3M	24.1M
Non Current Assets Total	918.0K	1.1M	3.3M	2.2M	1.7M	1.1M
Non Currrent Assets Other	98.0K	76K	2.4M	1.8M	1.3M	1.3M
Cash And Short Term Investments	34.6M	47.1M	103.6M	91.0M	53.7M	51.5M
Common Stock Shares Outstanding	2.5M	92.8K	31.9M	37.8M	38.6M	40.6M
Liabilities And Stockholders Equity	37.2M	48.3M	108.6M	96.0M	56.7M	54.4M
Non Current Liabilities Total	8K	281.0K	88.2M	5.1M	24.9M	0.0
Other Current Assets	1.7M	220K	3.4M	4.5M	857K	1.6M
Other Stockholder Equity	698.6M	4.7M	254.6M	270.7M	278.8M	292.7M
Total Liab	9.7M	94.5M	14.2M	34.9M	38.4M	27.6M
Property Plant And Equipment Gross	820K	273K	882K	414K	464K	717.8K
Total Current Assets	36.3M	47.2M	105.3M	93.7M	55.0M	52.9M
Accumulated Other Comprehensive Income	1K	(5.5M)	0.0	(178K)	9K	9.5K
Short Term Debt	6.0M	1.4M	762K	556K	25.8M	27.1M
Common Stock	3K	4K	11K	1K	4.6K	4.9K
Capital Surpluse	698.6M	718.8M	254.6M	270.7M	243.6M	436.4M
Property Plant Equipment	117.1K	1.0M	242K	148K	170.2K	245.8K
Other Assets	1.0	76.4K	0.0	1.8M	2.1M	2.2M
Net Tangible Assets	(28.4M)	(46.2M)	89.2M	55.7M	64.0M	67.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for Viracta Stock Analysis

When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Viracta Historical Balance Sheet

About Viracta Balance Sheet Analysis

Viracta Therapeutics Balance Sheet Chart

Retained Earnings

Accounts Payable

Viracta Therapeutics balance sheet Correlations

Viracta Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Viracta Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for Viracta Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Property Plant And Equipment Gross	+ 0.98	Property Plant And Equipment Net
Total Liab	+ 0.89	Non Current Liabilities Total

Property Plant And Equipment Gross	- 0.95	Other Stockholder Equity
Other Stockholder Equity	- 0.93	Property Plant And Equipment Net
Cash	- 0.92	Net Debt
Other Stockholder Equity	- 0.68	Non Current Assets Total
Total Liab	- 0.64	Total Stockholder Equity
Non Current Liabilities Total	- 0.54	Total Stockholder Equity